Bristol-Myers highlights increased cholesterol awareness as benefit of Questran switch.
This article was originally published in The Tan Sheet
BRISTOL HIGHLIGHTS CHOLESTEROL EDUCATION RESULTING FROM QUESTRAN SWITCH in making its case for approval of the switch application during a joint meeting of the Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Committees on Sept. 27. "We need to focus more educational effort on the professional as well as the consumer, and the over-the-counter product availability is going to make that possible," Virgil Brown, MD, Emory University School of Medicine, said in a presentation to the committee on behalf of Bristol-Myers Squibb.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC